Evidence map›Paper›PMID 39211152›Full record

ArticlebioRxiv : the preprint server for biology2024

A novel and potent MICA/B antibody is therapeutically effective in

Ryan R Kowash, Manoj Sabnani, Laura T Gray, Qing Deng, Luc Girard, Yujiro Naito, Kentaro Masuhiro, John D Minna, David E Gerber, Shohei Koyama and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ryan R Kowash
Manoj Sabnani
Laura T Gray
Qing Deng
Luc Girard
Yujiro Naito
Kentaro Masuhiro
John D Minna
David E Gerber
Shohei Koyama
Zhiqian Lucy Liu
Hemanta Baruah

Funding

Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLCR01CA276058 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Esra Akbay, Anthony J Davis · 2023 to 2026
$2.2M
Overcoming Therapy Resistance in SCLCR01CA289500 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Esra Akbay · 2024 to 2026
$1.5M
NCI NIH HHS R01 CA276058NCI NIH HHS R01 CA289500
6 · The paper itself

Abstract

Concurrent

Identifiers

PMID39211152
PMCPMC11361202

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.